Xylem Q1 2026: Revenue Grows 1.5% YoY, EPS Up, but Order Trends Remain Soft

What happened

Xylem reported Q1 2026 revenue of $2.1 billion, up approximately 1.5% year-over-year, with adjusted EPS rising 9%, echoing the beat-and-raise pattern that has propelled shares. However, the DeepValue report's concerns persist: total backlog declined 8.3% YoY by September 2025, and organic orders dipped 2% in Q3 2025, signaling that revenue growth is being driven by backlog conversion rather than fresh demand. Management cited 'strong execution' and 'solid demand,' but the report highlights a rising reliance on restructuring—$70 million in charges and 529 planned job cuts in 2025 alone—to sustain margins, which reached 23.2% adjusted EBITDA in Q3 2025 but may not be durable if orders slow further. The stock, at ~$116 after the April 2026 tariff selloff, remains well below the report's $140+ levels and its $165 trim threshold, offering a more attractive entry but still far from the $120 'attractive' zone. The combination of softening orders, premium multiples (28x 2025 EPS before the drop), and a balance sheet loaded with $8 billion in goodwill leaves limited margin of safety unless order trends re-accelerate convincingly.

Implication

The Q1 print confirms Xylem can still deliver near-term earnings beats, but the structural pressure on orders and backlog—down 8.3% YoY and organic orders negative—means growth is increasingly reliant on past wins and cost cuts. The DeepValue report's base case of 4% organic growth and 22% EBITDA margins implies a fair value of ~$145, but with the stock now ~$116 after tariff fears, the risk/reward has improved but remains skewed: a bear scenario to $115 is still plausible if orders stay weak. Investors should monitor Q2 2026 orders and backlog data; a re-acceleration above 5% organic order growth would upgrade the thesis, while another quarter of declines would confirm the bear case. The one-sentence takeaway: wait for concrete evidence that demand is re-accelerating before paying up for a story that still trades at 30x-plus earnings.

Thesis delta

The Q1 2026 results provide no decisive catalyst to shift the DeepValue report's WAIT rating. Revenue growth is modest, orders remain soft, and the margin expansion is increasingly tied to restructuring rather than organic mix improvement. The stock's decline from $140 to ~$116 brings it closer to the attractive entry ($120), but without a clear upturn in orders, the thesis remains 'wait' rather than 'buy.'